로딩 중…
지수 로딩 중…
Curiox BioSystems
445680· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩53,000-10.32%
2026-06-19
Price Chart
Curiox BioSystems+54.07%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 911.77B KRW |
| Revenue | 5.55B KRW |
| Net Income | -26.20B KRW |
| Total Assets | 77.73B KRW |
| Net Assets | 51.72B KRW |
| Employees | 23 |
| Value | |
| P/B | 17.63x |
| P/S | 164.15x |
| FCF Yield | -1.22% |
| Profitability | |
| ROE | -50.66% |
| ROA | -33.71% |
| Op. Margin | -225.80% |
| Revenue Growth | 43.72% |
| Earnings Growth | -1735.60% |
| Financial Health | |
| Debt Ratio | 150.29% |
| Total Debt | 1.94B KRW |
| FCF | -11.11B KRW |
| Cash | 10.06B KRW |
| Current Ratio | 1.59x |
| Performance | |
| 1Y Return | 54.07% |
| 1M Return | -35.76% |
| From 52W High | -64.48% |
| 1Y MDD | -62.03% |
| Trading | |
| Volume | 210,420 shares |
| Foreign Own. | 8.42% |
| Per Share | |
| EPS | -1,563 KRW |
| BPS | 3,021 KRW |
Company Info
Curiox Biosystems was established in 2018 to commercialize cell analysis process automation technology, developing a global sales network via subsidiaries in the United States, China, and Singapore. The company sells automated cell pre-processing equipment, plates, and accessories, featuring its unique Curiox C-FREE™ technology that significantly improves automation, data accuracy, and reproducibility in cell analysis. This non-centrifuge-based automated cell pre-processing product grants it a distinctive market position. Curiox Biosystems is headquartered in Geumcheon-gu, Seoul Metropolitan City.